USFDA completes inspection at Cadila Healthcare’s API facility at Dabhasa

14 Oct 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Cadila Healthcare’s Active Pharmaceutical Ingredients (API) manufacturing facility at Dabhasa, the group's largest API manufacturing site. The agency had inspected the site from October 7 to 11, 2019. This was a CGMP audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×